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ABSTRACT 
 
Phenylephrine (PE) induces cardiac hypertrophy through multiple signaling pathways including pathways 
involving protein kinase C (PKC) activation. Docosahexaenoic acid (DHA), an omega-3 fatty acid, has been 
shown to reduce the PE-induced hypertrophic responses.  However, the effects of DHA on PKC activation 
and  translocation  are  controversial.  The  present  study  investigates  the  effect  of  DHA  on  PE-induced 
activation  of  PKC.  The  results  indicate  that  PE  induces  PKCα  translocation  (from  cytosol  to  plasma 
membranes) and activation in cardiomyocytes during the hypertrophic responses. Although DHA itself has 
no significant effect on basal PKC translocation and activation, it effectively reduced PE-stimulated PKC 
translocation and activation. The results of the present study suggest a possible mechanism explaining how 
dietary fish oil may inhibit development of cardiac hypertrophy and therefore may be an attractive dietary 
agent for preventing cardiac hypertrophy in patients with heart failure.  
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INTRODUCTION 
 
Congestive heart failure is a major cause of morbidity and 
mortality  from  cardiovascular  disease.    In  the  United 
States, 4.8 million Americans suffer from heart failure and 
the  mortality  approaches  50%  over  5  years.    Despite 
current therapies for heart failure, mortality remains high.  
The  cost  for  treating  heart  failure  exceeds  30  billion 
dollars  per  year.  Progressive  hypertrophy  of 
cardiomyocytes  can  lead  to  heart  failure  and  increased 
morbidity.    Cardiac  hypertrophy,  which  is  commonly 
characterized by an increase in size of cardiomyocytes via 
a relative increase in cellular proteins in the absence of cell 
division  (Morgan  and  Baker,  1991;  Rupp  et  al,  1992), 
usually occurs as a compensatory mechanism secondary to 
increased  workload  in  patients  with  hypertension  or 
decreased  muscle  mass  following  myocardial  infarction 
(Dhalla et al, 1987). Since we believe that modification of 
dietary  factors  has  widespread  effects  upon  the 
development  of  cardiovascular  diseases,  our  group  has 
been  interested  in  dietary  factors  that  modulate  the 
development  of  heart  failure.    Most  dietary  factors  (ie. 
lipid  intake,  folic  acid)  affect  the  development  of 
atherosclerosis. Recent  data from epidemiological (Bang 
et al, 1976; Albert, 1998; Kris-Etherton et al, 2002) and 
prospective  randomized  clinical  trials  (Burr  et  al,  1989; 
Singh et al, 1997; GISSI-Prevenzione, 1999) suggests that 
omega-3 polyunsaturated fatty  acids may also affect the 
development  of  cardiac  arrhythmias  and  prevent  sudden 
death.  We have been studying the effects of omega-3 fatty 
acids  upon  the  cardiac  hypertrophic  response.    In  our 
initial  studies  (Siddiqui  et  al,  2004),  we  found  that  the 
omega-3  fatty  acid,  docosahexaenoic  acid  (DHA), 
inhibited  the  cardiomyocyte  hypertrophic  response  to 
phenylephrine (PE).  This study was aimed at identifying a 
signalling pathway by which DHA might inhibit cardiac 
hypertrophy. 
 
Activation  of  PKC  is  known  to  affect  multiple 
cardiovascular functions, including vascular permeability, 
cell migration, and growth (Lynch et al, 1990; Naruse and 
King, 2000); extracellular matrix production (Smirnov et  
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al,  1989;  Cagliero  et  al,  1991;  Naito  et  al,  2002)  and 
expression  of  various  cytokines  (Okada  et  al,  1998; 
Kondo  et  al,  2000);  ion  conductance  and  transport 
activity (Aviv, 1994); intracellular calcium homeostasis 
and  properties  of  contractile  proteins  (Bowman  et  al, 
1997); ischemic preconditioning of the heart (Strasser et 
al, 1999);  genesis  of arrhythmias (Mochly-Rosen et al, 
2000); and induction of cardiac hypertrophy  (Jalili et al, 
1999b;  Sabri  and  Steinberg,  2003).    While  PKC’s 
importance  in  cardiovascular  functions  cannot  be 
doubted,  its  precise  involvement  is  poorly  understood 
and unquestionably complex. 
 
The  PKC  family  of  serine-threonine  kinases  functions 
downstream  of  nearly  all  membrane-associated  signal 
transduction pathways involved in myocardial hypertrophy 
(Molkentin and Dorn, 2001). The three groups of the PKC 
family  of  kinases  comprise  approximately  13  different 
isozymes  [Conventional  (PKCα,  -β  I,  -β  II,  -γ),  novel 
(PKCδ, -ε, -θ, -η, -µ), and atypical (PKCζ, -ι, -ν, -λ)]. 
Once activated, PKC isozymes translocate from cytoplasm 
to  discrete  subcellular  membrane  sites  (Mochly-Rosen, 
1995). Many observations suggest that different isoforms 
of PKC are recruited to membranes with different stimuli, 
phosphorylate different sets of cellular substrates, and may 
regulate  different  cellular  functions.  PKC 
activation/translocation  is  initiated  during  hypertrophic 
responses  by  a  variety  of  stimuli  including  pressure 
overload  (Gu  and  Bishop,  1994;  Jalili  et  al.,  1999a; 
Takeishi et al., 1999; De Windt et al., 2000), bradykinin 
(Clerk  et  al,  1996),  hypoxia  (Goldberg  et  al,  1997), 
myotropin (Sil et al, 1998), norepinephrine (Rohde et al, 
2000),  angiotensin  II  (Rouet-Benzineb  et  al,  2000), 
endothelin-1  (Ito  et  al,  1997),  and  mechanical  stress 
(Yamazaki et al, 1995). Although PKCα, -βII, -δ, and -ε 
are broadly distributed in the cytoplasm of non-stimulated 
cardiomyocytes (Braz et al, 2002), recent studies implicate 
PKCα  as  a  critical  regulator  of  the  cardiomyocyte 
hypertrophic  response,  in  part  via  ERK1/2–MAPK 
activation (Braz et al, 2002). 
 
Conflicting reports about the role of DHA in regulating 
PKC activities have appeared in the literature.  DHA has 
been  shown  to  both  activate  and  inhibit  PKC  activity 
and  its  translocation  to  membranes.  For  example, free 
DHA, DHA containing phospholipids or diacylglycerol 
caused  translocation  and  activation  of  PKC  in  several 
cellular systems (Hrelia et al, 1992; Hardy et al, 1994; 
Giorgione et al, 1995; Goldberg and Zidovetzki, 1997; 
Huang  et  al,  1997).    In  contrast,  a  number  of  studies 
have  suggested  that  DHA  actually  inhibits  PKC 
activation (Mirnikjoo et al, 2001).  For example, studies 
have shown that DHA was a highly potent inhibitor of 
phosphatidylserine  (PS)-  and  diolein  (DO)-stimulated 
PKC  in  rat  colon  cells  (Holian  and  Nelson,  1992). 
Furthermore,  DHA  also  reduced  activation  of 
membrane-bound  PKC  in  isolated  cardiomyocytes 
(Bordoni  et  al,  1992)  and  suppressed  PKC  activity  in 
thioglycollate-induced  rat  peritoneal  macrophages 
(Tappia  et  al,  1995).  The  present  investigation  was 
therefore  undertaken  to  clarify  the  effects  of  DHA  on 
PKCα  activation  during  hypertrophic  responses  in 
neonatal cardiomyocytes. 
MATERIALS AND METHODS 
 
Materials 
The  cardiomyocyte  isolation  kit  was  purchased  from 
Worthington Biochemical Corporation (Lakewood, NJ). 
Horse  and  fetal  bovine  serum  were  obtained  from 
Hyclone (Logan, UT). DHA and other fatty acids were 
obtained from Nu Chek Prep, Inc. (Elysian, MN). Anti-
ANF  antibody  was  obtained  from  Peninsula 
Laboratories, Inc. (San Carlos, CA). Anti-sarcomeric α-
actinin  came  from  Sigma-Aldrich  Chemical  Co.  (St. 
Louis, MO) and anti-PKCα antibody was from Upstate 
Biotechnologies, Inc. (Lake Placid, NY). Anti-mouse or 
anti-rabbit  Alexa  Fluor  546  and  480  antibodies  were 
purchased  from  Molecular  Probes  (Eugene,  OR). 
Phenylephrine  and  all  other  chemicals  were  obtained 
from Sigma-Aldrich Chemical Co. 
 
Isolation of cardiomyocytes 
Neonatal cardiomyocytes were obtained using an isolation 
system  from  Worthington  Biochemical  Corporation. 
Hearts were harvested from 1- to 3-day-old Wistar rats. 
The isolated hearts were cleared of connective tissue and 
atria, minced into approximately 1 mm blocks, and then 
incubated with trypsin for overnight digestion. The next 
day,  trypsin  activity  was  neutralized  by  the  trypsin 
inhibitor  and  the  tissues  were  further  digested  with 
collagenase.  Single  cells  were  obtained  by  filtering  the 
digest  through  a  70  µm  filter.  Cells  were  pre-plated  to 
remove  fibroblasts,  and  cardiomyocytes  were  isolated 
using  the  Worthington’s  protocols.  Dead  cells,  cellular 
debris,  and  contaminating  fibroblasts  were  further 
removed by centrifugation on a 5 ml layer of an Optiprep 
density  gradient  solution  (Axis-Shield  PoC,  Oslo, 
Norway). This preparation yielded a 95% pure population 
of  cardiomyocytes  as  analyzed  by  sarcomeric  α-actinin 
staining (Haq et al, 2000).  Isolated cardiomyocytes were 
cultured for 24 hr in a humidified incubator in the presence 
of 95% O2/5% CO2. The cells were grown on laminin- and 
collagen-coated  plates  in  F-10  medium  containing  10% 
horse  serum,  5% (v/v) fetal  bovine  serum,  100-units/ml 
penicillin,  100µg/ml  streptomycin,  and  0.1  mM 
bromodeoxyuridine  (to  prevent  low-level  non-myocyte 
proliferation).  Cardiomyocytes  were  washed  twice  with 
serum-free  medium  (F-10  medium  without  serum)  and 
then  treated  with  DHA  (5  µM)  under  serum-free 
conditions for 24 hr. Cells were then incubated with PE 
(100 µM) in fresh medium with or without a fresh supply 
of DHA (5 µM). Cells were incubated for another 48 hr in 
a humidified incubator in the presence of 95% O2 and 5% 
CO2 to induce hypertrophic responses. The DHA solution 
was  made  fresh  each  time  from  a  pure  sealed  stock 
solution by dissolving the fatty acid in ethanol so that the 
final concentration of ethanol added to the culture medium 
did  not  exceed  0.05%.  Control  cells  were  treated  with 
equal amounts of ethanol in each case. 
 
Characterization of hypertrophy 
Hypertrophy  was  induced  by  incubating cardiomyocytes 
under serum-free conditions in the presence of 100 µM PE 
for 48 hr under the incubation conditions described above.  
Incubation in the presence of serum-free conditions for a 
total of 78 hr does not result in the detachment of cells  
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from laminin-coated surfaces, and morphological features 
under the microscope appear to be normal. Hypertrophy 
was assessed by monitoring cell surface area, expression 
of sarcomeric α-actinin, and ANF. 
 
Cardiac myocyte surface area 
The  cardiac  myocyte  surface  area  was  measured  as 
described  previously  (Simpson,  1983).  Cells  were 
observed  under  a  Leica  DMR  microscope  (Leica 
Microskopie  und  systeme,  GmbH,  Postfach,  Germany) 
and pictures were taken with a MagnaFire digital camera 
(Optronics,  Goleta,  CA)  for  analysis.  All  cells  were 
randomly selected by a blinded operator for tracing the 
surface area of 10 cells in each group. Result represents 
the  mean±SE  of  three  experiments  and  analyzed  by 
ANOVA  and  Tukey’s  multiple  comparison  tests. 
Significant  differences  within  groups  are  reported. 
***P<0.05. 
 
PKC activity 
The  total  PKC  activity  in  membrane  fractions  was 
assayed  using  a  PKC  assay  kit  containing  a  specific 
substrate peptide for PKC in the presence of [γ-
32P] ATP 
and an inhibitor mixture that blocks protein kinase A and 
calmodulin  kinase  activities  (Upstate  Biotechnologies, 
Inc,  Lake  Placid,  NY).  The 
32P-substrate  from  each 
treatment was separated from residual [
32P] ATP using 
p81  phosphocellulose  paper,  and  the  radioactivity 
incorporated  into  the  substrate  was  measured  by 
scintillation  counting  as  described  previously  (Siddiqui 
and Exton, 1992). 
 
Subcellular localization and activation of PKC 
Following  treatment  with  DHA  and  subsequent 
stimulation with PE, the cells were homogenized and the 
cytosolic  and  membrane  fractions  isolated  by 
centrifugation  at  100,000  x  g  for  one  hr  at  4
oC.    The 
membrane proteins were separated on 8% SDS-PAGE as 
described (Siddiqui et al, 2004). The relative distribution 
of PKCα was determined by densitometric analysis using 
a  KODAK  imaging  system  (Eastman  Kodak  company, 
Rochester, NY). 
 
Translocation of PKC in cardiomyocytes 
Following  treatment with PE and DHA, cardiomyocytes 
were fixed with 3% paraformaldehyde and then blocked 
with  1%  bovine  serum  albumin  (BSA)  in  phosphate-
buffered  saline  (PBS).  Proteins  were  detected  using 
specific  antibodies  (anti-ANF,  anti-α-sarcomeric  actinin, 
anti-PKCα  antibodies)  in  a  1:200  dilution  in  blocking 
buffer and either Alexa 546- or Alexa 480-labelled anti-
mouse  or  anti-rabbit  (1:200  dilution  in  blocking  buffer) 
antibodies.  Cells  were  examined  under  a  fluorescence 
microscope  and  pictures  were  taken  using  a  MagnaFire 
digital camera for analysis. 
 
Statistical analysis 
Results  typically  represent  three  experiments  in  each 
group  and  were  analyzed  by  ANOVA  and  Tukey’s 
multiple  comparison tests.  Significant  differences  within 
groups are reported. ***P<0.05. 
RESULTS AND DISCUSSION 
 
We previously reported that DHA reduces PE-hypertrophy 
through  inhibition  of  the  Ras→Raf-1→Erk1/2→p90rsk 
pathway  (Siddiqui  et  al,  2004).    However,  there  is 
evidence that multiple signaling pathways are involved in 
the progression of cardiac hypertrophy (Hefti et al, 1997; 
Aoki et al, 2000; Molkentin and Dorn, 2001; Bueno and 
Molkentin, 2002), including those involving PKC (Gu and 
Bishop, 1994; Clerk et al, 1996; Goldberg et al, 1997; Ito 
et al, 1997; Sil et al, 1998; Jalili et al, 1999a; Takeishi et 
al, 1999; De Windt et al, 2000; Rohde et al, 2000; Rouet-
Benzineb et al, 2000). However, involvement of DHA in 
the activation of PKC remains controversial (Holian and 
Nelson,  1992;  Hrelia  et  al,  1992;  Hardy  et  al,  1994; 
Giorgione  et  al,  1995;  Goldberg  and  Zidovetzki,  1997; 
Huang et al, 1997; Mirnikjoo et al, 2001). For this reason, 
we  investigated  the  effect  of  DHA  on  PKC  activation 
during PE-induced cardiac hypertrophy. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1. Effect of PE and DHA on cell surface area. 
Cardiomyocytes were treated with either ethanol (control), 
serum free media or DHA (5 µM in serum-free conditions) 
for 24 hr and then incubated with/without PE (100 µM) for 48 
hr.  Data are expressed as mean ± SEM for examination of 10 
cells in each group from three separate experiments and were 
analyzed by ANOVA and Tukey’s multiple comparison tests. 
Significant differences within groups are reported. 
***P<0.05. 
 
 
Our  results  demonstrated  that  cardiomyocytes  undergo 
hypertrophy upon PE exposure (Figure 1). PE induced an 
increase in cell surface area by two fold (P<0.05).  DHA 
itself had no effect on cardiac cell size; however, DHA 
reduced the PE-stimulated increases in cell surface area. 
Results  presented  in  Figure  2  demonstrated  that  PE 
treatment of cells caused extensive synthesis of sarcomeric 
α-actinin  with  well-organized  z-band  structure  (as 
indicated  by solid arrows). The PE-stimulated cells also 
exhibited expression of atrial natriuretic factor (ANF) (as 
indicated by dotted arrows), in characteristic perinuclear 
rings. Approximately  70-85%  of the PE-stimulated cells 
under  20x  magnification  exhibit  these  rings.  DHA 
treatment itself had no effect on cardiomyocytes; however, 
pretreatment of cells  with DHA  reduced the expression of  
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Figure 2. Effect of PE and DHA on α-actinin and ANF expression. Cardiomyocytes were treated with PE and DHA as 
described in the legend of Figure1. Solid arrows indicate the expression of sarcomeric α-actinin in z-bands (green 
fluorescence) whereas dotted arrows indicate expression of ANF (red fluorescence).  Results are a typical representation of 
five experiments. 
Control 
PE (100 µM) 
DHA (5 µM) 
DHA (5 µM) 
PE (100 µM) 
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sarcomeric α-actinin and ANF upon PE stimulation. ANF, 
a  universal  and  specific  marker  of  cardiac  hypertrophy 
(Decker  et  al,  1995;  Knowlton  et  al,  1995),  was 
particularly affected. However, its role in the development 
of hypertrophy is not yet clear (Ito et al, 1993; Cao and 
Gardner,  1995;  Calderone  et  al,  1998;  Silberbach  et  al, 
1999). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.  Effect of PE and DHA on PKC activity. 
Cardiomyocytes were treated with PE and DHA as described in 
the legend of Figure1.  The total PKC activity in membrane 
fractions of cardiomyocytes was assayed as described in the 
Material and Methods section.  Results are expressed as the 
mean±SE for three experiments and analyzed by ANOVA and 
Tukey’s multiple comparison tests. Significant differences 
within groups are reported. ***P<0.05. 
 
 
We  next  evaluated  the  effect  of  DHA  upon  PKC 
enzymatic  activity.    Results  presented  in  Figure  3 
indicated  that  PE  increased  PKC  activity  in  membrane 
fractions  four  fold  (P<0.05),  as  determined  by 
phosphorylation of exogenous PKC specific peptide. DHA 
had  no  effect  upon  basal  PKC  activity,  while  DHA 
substantially  reduced  PE-induced  activation  of  PKC.  
Since this in vitro PKC kinase assay did not distinguish 
between  PKC  isoenzymes,  we  next  investigated  DHA 
effects  upon  PKCα, the  primary  PKC  isoenzyme  in 
cardiac  tissue.    Using  specific  anti-PKCα  antibodies, 
results  of  western  analysis  indicated  that  PE  treatment 
indeed  caused  a  2.8-3.2  fold  (P<0.05)  increased 
accumulation of PKCα in the membrane fractions (Figure 
4).  DHA  itself  had  no  significant  effect  on  PKCα 
translocation  but  effectively  reduced  PE-stimulated 
increases  in  PKC  translocation  to  membranes to  a  non-
significant  1.5-2.2  fold.  Translocation  of  PKC  to  the 
membranes  is  well  recognized  as  a  mechanism  for 
activation  of  classical  PKC  isozymes  including  PKCα 
(Parker  and  Murray-Rust,  2004;  Spitaler  and  Cantrell, 
2004).  Next, we evaluated  translocation  of PKCα  using 
immunohistochemical analysis. Results shown in Figure 5 
demonstrated  that  PKCα  is  diffusely  present throughout 
the  cytoplasm  in  non-treated  cells.  PE  treatment  of 
cardiomyocytes caused translocation and accumulation of 
PKCα in membranes as evidenced by the disappearance of 
most  of  the  diffuse  staining  from  cytoplasm  and 
appearance  of  intense  staining  along  the  cytoskeletal 
structure.    In  DHA  treated  cells,  most  of  the  PKCα 
remained  present  throughout  the  cytoplasm.  However, 
DHA partially inhibited PE-induced PKCα translocation 
to membrane sites. 
 
 
 
 
 
 
Figure 4.  Effect of PE and DHA on PKCα distribution in 
membranes. Cardiomyocytes were treated with PE and DHA as 
described in the legend of Figure 1. Membranes were isolated 
and separated on 8% SDS-PAGE as described in the Material 
and Methods section.  PKCα was detected by Western blotting 
using anti-PKCα antibodies and the relative distribution of 
PKCα was determined by densitometric analysis.  Results are a 
typical representation of three experiments. 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.  Effect of PE and DHA on PKCα translocation in 
cardiomyocytes. Cardiomyocytes were treated with PE and DHA 
as described in the legend of Figure 1. Proteins were detected 
using anti-PKCα specific antibody and visualized with Alexa 
546- (red fluorescence) labelled anti-mouse as described in the 
Material and Methods section.  Cells were examined under a 
fluorescence microscope and images were captured using a 
MagnaFire digital camera (Optronics) for analysis. Results are a 
typical representation of three experiments. 
 
 
Results  shown  in  Figures  3-5 indicated  that  DHA  itself 
had no significant effects upon PKCα translocation and 
activation, but DHA was very effective at reducing PE-
induced  PKC  translocation  to  membranes.  The 
hypertrophy  inhibitory  effect  of  DHA  is  unique  to  this 
fatty acid, since we have not observed inhibition of cardiac 
hypertrophy by other long chain fatty acids such as oleic 
acid,  linoleic  acid,  linolenic  acid,  arachidonic  acid,  and 
eicosapentaenoic  acid  (Siddiqui  et  al,  2004).  We  have 
found in another study (data not Shown) that feeding diets 
rich in omega-3 fatty acids with equal amounts of DHA 
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and EPA (10-12%) resulted in greater proportion of DHA 
incorporation in cardiac tissues (24%) than that  of EPA 
(3%).  It  appears  that  a  greater  proportion  of  DHA 
accumulation  in  cardiac  tissues  may  be  responsible  for 
some of the unique effects of DHA in the cardiovascular 
system. However, our data  does not imply that DHA is 
unique  in  effecting  cardiac  hypertrophy  through  PKC 
activation  or  translocation  since  these  effects  were  not 
evaluated with different fatty acids. 
 
In this study, we evaluated the effects of DHA upon the 
hypertrophic  response  induced  by  the  alpha-adrenergic 
agonist,  PE.  Although  other  important  hypertrophic 
growth  factors  for  the  heart  (i.e.,  angiotensin  II, 
endothelin) exist, the effect of DHA upon the hypertrophic 
response  to  these  growth  factors  will  require  additional 
study.  Similarly, there are also other signaling pathways 
that may contribute to PE-stimulated cardiac hypertrophy.  
Further studies are required to investigate if DHA has any 
effect  on  other  signaling  pathways.    Moreover,  the 
molecular  mode  of  action  by  which  DHA  affects  PKC 
activity  remains  unknown.  We  hypothesize  that  DHA 
incorporates  into  the  cell  membrane  where  it  alters 
structure  and  physical  properties  of  the  cell  membrane. 
These  alterations  inhibit  interaction  (translocation)  and 
activation  of  PKC  within  the  cell  membrane.  The  net 
effect is  diminished activation  of the enzyme. It is also 
possible  that  DHA  inhibits  phospholipase  C  and 
generation  of  inositol  triphosphate  and  diacylglycerol 
activators of PKC. 
 
CONCLUSIONS 
 
Our studies demonstrate that DHA alone has no significant 
effects  upon  PKCα  translocation  and  activation. 
Conversely,  this  fatty  acid  effectively  prevents  the 
activation  and  translocation  of  PE-induced  PKCα.  We 
conclude that DHA inhibition of PE-induced activation of 
PKCα  contributes  to  the  anti-hypertrophic  actions  of 
DHA.  The  results  of  this  in  vitro  study  need  to  be 
confirmed in vivo. If confirmed, DHA in fish oil may be 
an important dietary agent that modifies the development 
of cardiac hypertrophy. 
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